Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET plus ), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm plus ) and progression on gefitinib

被引：0
|
作者：
Wu, Yi-Long
Yang, James Chih-Hsin
Park, Keunchil
Xu, Lianzhe
Bladt, Friedhelm
Johne, Andreas
Li, Peiqi
Zheng, Hongxia
Massimini, Giorgio
机构：
[1] GGH, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Innovat Canc Med Inst, Seoul, South Korea
[5] Merck Serono Pharmaceut R&D Co Ltd, Global Biostat, Beijing, Peoples R China
[6] Merck KGaA, Translat Innovat Platform Oncol, Global Res & Dev, Darmstadt, Germany
[7] Merck KGaA, Clin Pharmacol, Darmstadt, Germany
[8] Merck Serono Pharmaceut R&D Co Ltd, Global Clin Dev Ctr, Beijing, Peoples R China
[9] EMD Serono, Global Res & Early Dev, Boston, MA USA
[10] Merck KGaA, Global Res & Early Dev, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps8121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8121
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS)
    Wu, Y.
    Mok, T.
    Chu, D.
    Han, B.
    Liu, X.
    Zhang, L.
    Zhou, C.
    Rukazenkov, Y.
    Duffield, E.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL)
    Garcia Campelo, Rosario
    Felip, Enriqueta
    Massuti, Bartomeu
    Majem, Margarita
    Carcereny Costa, Enric
    Palmero, Ramon
    Angel Molina-Vila, Miguel
    Martinez, Pablo
    Luis Marti-Ciriquian, Juan
    Alonso-Jaudenes Curbera, Guillermo
    Pallares, Cinta
    Cardenal, Felipe
    Carmen Gonzalez-Arenas, Maria
    Mayo-de las Casas, Clara
    Sanchez-Ronco, Maria
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)
    Fukuoka, M.
    Wu, Y.
    Thongprasert, S.
    Yang, C.
    Chu, D.
    Saijo, N.
    Watkins, C.
    Duffield, E.
    Armour, A.
    Mok, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] First-line gefitinib in Caucasian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC): Results from a multinational, prospective,,open-label, single-arm Phase IV study
    Ostoros, G.
    Cobo, M.
    Ciuleanu, T.
    McCormack, R.
    Webster, A.
    Milenkova, T.
    Douillard, J. Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S820 - S820
  • [45] Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non-small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.
    Takeda, Masayuki
    Seto, Takashi
    Hayashi, Hidetoshi
    Okada, Morihito
    Azuma, Koichi
    Sugawara, Shunichi
    Daga, Haruko
    Hirashima, Tomonori
    Yonesaka, Kimio
    Urata, Yoshiko
    Murakami, Haruyasu
    Saito, Haruhiro
    Kubo, Akihito
    Sawa, Toshiyuki
    Miyahara, Eiji
    Nogami, Naoyuki
    Yamanaka, Takeharu
    Nakanishi, Yoichi
    Nakagawa, Kazuhiko
    Okamoto, Isamu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).
    Yoshioka, Hiroshige
    Mitsudomi, Tetsuya
    Morita, Satoshi
    Yatabe, Yasushi
    Negoro, Shunichi
    Okamoto, Isamu
    Seto, Takashi
    Satouchi, Miyako
    Tada, Hirohito
    Hirashima, Tomonori
    Asami, Kazuhiro
    Katakami, Nobuyuki
    Takada, Minoru
    Shibata, Kazuhiko
    Kudoh, Shinzoh
    Shimizu, Eiji
    Saito, Hiroshi
    Toyooka, Shinichi
    Nakagawa, Kazuhiko
    Fukuoka, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] PHASE IB STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF OLAPARIB (AZD2281) PLUS GEFITINIB IN PATIENTS (P) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (P). (NCT=1513174/GECP-GOAL)
    Garcia Campelo, Rosario
    Felip, Enriqueta
    Massuti, Bartomeu
    Majem, Margarita
    Carcereny, Enric
    Palmero, Ramon
    Angel Molina-Vila, Miguel
    Cajal, Rosana
    Sanchez-Ronco, Maria
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S914 - S914
  • [48] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)
    Goto, Koichi
    Nishio, Makoto
    Yamamoto, Noboru
    Chikamori, Kenichi
    Hida, Toyoaki
    Maemondo, Makoto
    Katakami, Nobuyuki
    Kozuki, Toshiyuki
    Yoshioka, Hiroshige
    Seto, Takashi
    Fukuyama, Tamaki
    Tamura, Tomohide
    LUNG CANCER, 2013, 82 (01) : 109 - 114
  • [49] A multicenter randomized phase II study of paclitaxel (P) and carboplatin (C) versus oral vinorelbine (oV) and carboplatin (C) as second-line treatment in patients (pts) with non-small cell lung cancer (NSCLC) pretreated with non-platinum based chemotherapy
    Agelaki, S.
    Syrigos, K.
    Polyzos, A.
    Agelidou, A.
    Handrinos, V
    Kotsakis, A.
    Christophyllakis, Ch
    Vardakis, N.
    Georgoulias, V
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S447 - S448
  • [50] Phase IB/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer (vol 36, pg 3101, 2018)
    Wu, Y-L
    Zhang, L.
    Kim, D-W
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 261 - 261
12345